Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs.
between-subject variability
dog
modeling
pharmacokinetics
simvastatin
Journal
Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
Titre abrégé: J Vet Pharmacol Ther
Pays: England
ID NLM: 7910920
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
16
11
2020
accepted:
09
12
2020
pubmed:
29
12
2020
medline:
25
11
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Simvastatin, used orally to treat hyperlipidemia, exhibits highly variable pharmacokinetics (PKs) in humans. The aim of this study was to investigate simvastatin PKs using noncompartmental analysis and population PK models following a single oral administration of two doses (20 and 80 mg) in dogs. Forty beagle dogs were randomly divided into two groups corresponding to the two doses. Blood samples were collected from each group according to the assigned schedule after oral administration. The plasma concentration of simvastatin was determined using liquid chromatography-tandem mass spectrometry. The area under the curve and maximum concentration of simvastatin increased in a dose-dependent manner with high variability. A two-compartment model with first-order absorption (K
Substances chimiques
Simvastatin
AGG2FN16EV
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-341Subventions
Organisme : Kyungsung University
Organisme : Ministry of Education
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Alhadab, A. A., & Brundage, R. C. (2020). Population pharmacokinetics of sertraline in healthy subjects: A model-based meta-analysis. The AAPS Journal, 22(4), 73. https://doi.org/10.1208/s12248-020-00455-y
Almukainzi, M., Araujo, G. L., & Löbenberg, R. (2019). Orally disintegrating dosage forms. Journal of Pharmaceutical Investigation, 49(2), 229-243. https://doi.org/10.1007/s40005-018-0408-2
Aslam, F. (2004). Over-the-counter statins. Lancet, 364(9432), 411-412. https://doi.org/10.1016/s0140-6736(04)16751-2
Baek, I. H. (2019). Pharmacokinetic modeling and simulation of etodolac following single oral administration in dogs. Xenobiotica, 49(8), 981-986. https://doi.org/10.1080/00498254.2018.1524185
Baek, I.-H., Lee, B.-Y., Kim, M.-S., & Kwon, K.-I. (2013). Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs. Xenobiotica, 43(10), 895-900. https://doi.org/10.3109/00498254.2013.782078
Baverel, P. G., Savic, R. M., & Karlsson, M. O. (2011). Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. Journal of Pharmacokinetics and Pharmacodynamics, 38(1), 63-82. https://doi.org/10.1007/s10928-010-9177-x
Chao, Y., Chen, J., Hunt, V., Kuron, G., Karkas, J., Liou, R., & Alberts, A. (1991). Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. European Journal of Clinical Pharmacology, 40(1), S11-S14. https://doi.org/10.1007/BF03216281
Chiaro, J. A., O'Donnell, P., Shore, E. M., Malhotra, N. R., Ponder, K. P., Haskins, M. E., & Smith, L. J. (2014). Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs. Journal of Bone and Mineral Research, 29(12), 2610-2617. https://doi.org/10.1002/jbmr.2290
Figueiredo, V. P., Azevedo, M. A., Bahia, M. T., de Figueiredo Diniz, L., Melo, L., Gonçalves, K. R., de Lima, W. G., Talvani, A., Caldas, I. S., da Silva do Nascimento, A. F., & Torres, R. M. (2011). Low doses of simvastatin therapy ameliorate cardiac inflammatory remodeling in Trypanosoma cruzi-infected dogs. The American Journal of Tropical Medicine and Hygiene, 84(2), 325-331. https://doi.org/10.4269/ajtmh.2011.10-0451
Gough, K., Hutchison, M., Keene, O., Byrom, B., Ellis, S., Lacey, L., & McKellar, J. (1995). Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Information Journal, 29(3), 1039-1048. https://doi.org/10.1177/009286159502900324
Ha, E.-S., Lee, S.-K., Choi, D. H., Jeong, S. H., Hwang, S.-J., & Kim, M.-S. (2020). Application of diethylene glycol monoethyl ether in solubilization of poorly water-soluble drugs. Journal of Pharmaceutical Investigation, 50(3), 231-250. https://doi.org/10.1007/s40005-019-00454-y
Hooker, A. C., Staatz, C. E., & Karlsson, M. O. (2007). Conditional weighted residuals (CWRES): A model diagnostic for the FOCE method. Pharmaceutical Research, 24(12), 2187-2197. https://doi.org/10.1007/s11095-007-9361-x
Hwang, J. G., Yu, K. S., & Lee, S. (2020). Comparison of the pharmacokinetics of highly variable drugs in healthy subjects using a partial replicated crossover study: A fixed-dose combination of fimasartan 120 mg and atorvastatin 40 mg versus separate tablets. Drug Design, Development and Therapy, 14, 1953-1961. https://doi.org/10.2147/dddt.S233732
Idkaidek, N. M., Najib, N. M., Arafat, T., & Al-Ghazawi, A. (2008). Population pharmacokinetics of atorvastatin, simvastatin & pravastatin after oral administration in humans. Saudi Pharmaceutical Journal, 16(1), 82-84.
Jonsson, E. N., & Karlsson, M. O. (1999). Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Computer Methods and Programs in Biomedicine, 58(1), 51-64. https://doi.org/10.1016/s0169-2607(98)00067-4
Kang, B. K., Lee, J. S., Chon, S. K., Jeong, S. Y., Yuk, S. H., Khang, G., Lee, H. B., & Cho, S. H. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. International Journal of Pharmaceutics, 274(1-2), 65-73. https://doi.org/10.1016/j.ijpharm.2003.12.028
Karlsson, M. O., & Savic, R. M. (2007). Diagnosing model diagnostics. Clinical Pharmacology and Therapeutics, 82(1), 17-20. https://doi.org/10.1038/sj.clpt.6100241
Keizer, R. J., Karlsson, M. O., & Hooker, A. (2013). Modeling and simulation workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT: Pharmacometrics & Systems. Pharmacology, 2(6), e50. https://doi.org/10.1038/psp.2013.24
Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2000). Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clinical Pharmacology and Therapeutics, 68(6), 592-597. https://doi.org/10.1067/mcp.2000.111414
Lai, J., Chen, J., Lu, Y., Sun, J., Hu, F., Yin, Z., & Wu, W. (2009). Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. An Official Journal of the American Association of Pharmaceutical Scientists, 10(3), 960-966. https://doi.org/10.1208/s12249-009-9292-4
Lindbom, L., Pihlgren, P., & Jonsson, E. N. (2005). PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Computer Methods and Programs in Biomedicine, 79(3), 241-257. https://doi.org/10.1016/j.cmpb.2005.04.005
Mauro, V. F. (1993). Clinical pharmacokinetics and practical applications of simvastatin. Clinical Pharmacokinetics, 24(3), 195-202. https://doi.org/10.2165/00003088-199324030-00002
McKiernan, B., Neff-Davis, C., Koritz, G., Davis, L., & Pheris, D. (1981). Pharmacokinetic studies of theophylline in dogs. Journal of Veterinary Pharmacology and Therapeutics, 4(2), 103-110. https://doi.org/10.1111/j.1365-2885.1981.tb00718.x
Najib, N. M., Idkaidek, N., Adel, A., Admour, I., Astigarraga, R. E., Nucci, G. D., & Dham, R. (2003). Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast & Zocor) in healthy human volunteers. Biopharmaceutics & Drug Disposition, 24(5), 183-189. https://doi.org/10.1002/bdd.347
Pedersen, T. R., & Tobert, J. A. (2004). Simvastatin: A review. Expert Opinion on Pharmacotherapy, 5(12), 2583-2596. https://doi.org/10.1517/14656566.5.12.2583
Platt, S. R., Coates, J. R., Eifler, D. M., Edwards, G. L., Kent, M., & Bulsara, K. R. (2013). Effect of treatment with simvastatin and cyclosporine on neurotransmitter concentrations in cerebrospinal fluid after subarachnoid hemorrhage in dogs. American Journal of Veterinary Research, 74(8), 1111-1117. https://doi.org/10.2460/ajvr.74.8.1111
Post, T. M., Freijer, J. I., Ploeger, B. A., & Danhof, M. (2008). Extensions to the visual predictive check to facilitate model performance evaluation. Journal of Pharmacokinetics and Pharmacodynamics, 35(2), 185-202. https://doi.org/10.1007/s10928-007-9081-1
Prueksaritanont, T., Qiu, Y., Mu, L., Michel, K., Brunner, J., Richards, K. M., & Lin, J. H. (2005). Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: Effects of gemfibrozil. Pharmaceutical Research, 22(7), 1101-1109. https://doi.org/10.1007/s11095-005-6037-2
Simard, C., O'Hara, G. E., Prévost, J., Guilbaud, R., Masseé, R., & Turgeon, J. (2001). Study of the drug-drug interaction between simvastatin and cisapride in man. European Journal of Clinical Pharmacology, 57(3), 229-234. https://doi.org/10.1007/s002280100298
Sirtori, C. R. (2014). The pharmacology of statins. Pharmacological Research, 88, 3-11. https://doi.org/10.1016/j.phrs.2014.03.002
Stubbs, R., Schwartz, M., Gerson, R., Thornton, T., & Bayne, W. (1990). Comparison of plasma profiles of lovastatin (mevinolin), simvastatin (epistatin) and pravastatin (eptastatin) in the dog. Drug Investigation, 2(2), 18-28. https://doi.org/10.1007/BF03258190
Sunkara, G., Reynolds, C. V., Pommier, F., Humbert, H., Yeh, C., & Prasad, P. (2007). Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Current Medical Research and Opinion, 23(3), 631-640. https://doi.org/10.1185/030079906x167471
Sutton, S. C. (2004). Companion animal physiology and dosage form performance. Advanced Drug Delivery Reviews, 56(10), 1383-1398. https://doi.org/10.1016/j.addr.2004.02.013
Tatham, L. M., Liptrott, N. J., Rannard, S. P., & Owen, A. (2019). Long-acting injectable statins-Is it time for a paradigm shift? Molecules, 24(15), 2685. https://doi.org/10.3390/molecules24152685
Todd, P. A., & Goa, K. L. (1990). Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs, 40(4), 583-607. https://doi.org/10.2165/00003495-199040040-00007
Torres, C. G., Olivares, A., & Stoore, C. (2015). Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells. Oncology Reports, 33(5), 2235-2244. https://doi.org/10.3892/or.2015.3850
Tothfalusi, L., & Endrenyi, L. (2012). Sample sizes for designing bioequivalence studies for highly variable drugs. Journal of Pharmacy & Pharmaceutical Sciences, 15(1), 73-84. https://doi.org/10.18433/j3z88f
US Food and Drug Administration. (2018). Bioanalytical method validation. Guidance for industry. US Department of Health and Human Services. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Veterinary Medicine. Available from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry